Receptor News and Research

RSS

AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing critical needs in cardiovascular health.

16 Jan 2025

T-DM1 reduces long-term risk of death in HER2-positive breast cancer patients

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared to trastuzumab alone, according to the final results of the phase 3 KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center.

16 Jan 2025

Tiny vesicles offer powerful new approach for cancer treatment

A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

16 Jan 2025

Pheno Therapeutics receives clinical trial authorization for novel multiple sclerosis therapeutic

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received clinical trial authorization (CTA) from the UK’s MHRA (Medicines and Healthcare products Regulatory Agency) for its lead candidate, PTD802.

15 Jan 2025

Unexpected viral reservoir: influenza A thrives in cattle mammary glands

Researchers uncover how influenza A virus infects dairy cattle, revealing the mammary gland's surprising role in viral replication and transmission through milk.

15 Jan 2025

Scientists discover how specific protein regions contribute to breast cancer

Researchers at Case Western Reserve University School of Medicine have discovered how specific protein regions contribute to breast cancer.

15 Jan 2025

New compounds show promise in treating retinitis pigmentosa

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness.

15 Jan 2025

Semaglutide improves glycemic control with automated insulin delivery

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin requirements and aiding weight management.

15 Jan 2025

Pancreatic cancer insights: How pORG classifications predict survival and guide treatment

Researchers identify distinct molecular and immune profiles that impact the prognosis of patients with metastatic pancreatic ductal adenocarcinoma.

15 Jan 2025

Genetic risk factor linked to increased susceptibility to SARS-CoV-2 infection

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus' ability to invade human cells. SARS-CoV-2 is the virus that spreads COVID-19.

15 Jan 2025

Pheno Therapeutics granted clinical trial authorization for lead multiple sclerosis therapeutic candidate PTD802

From Pheno Therapeutics 15 Jan 2025

CAR-NK cells offer safer, more accessible treatment for lymphoma

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to patients.

15 Jan 2025

Uncovering the neurobiological mechanisms of delta opioid receptor agonists

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions, current medications have several limitations, including slow action and adverse effects with long-term use. This underscores the urgent need for novel, rapidly-acting therapeutic agents with minimal side effects.

15 Jan 2025

New drug cocktail enhances CAR-T cells for cancer treatment

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust immune system CAR-Ts (chimeric antigen receptor-T cells) to fight cancer.

13 Jan 2025

Study reveals route of entry for Semliki Forest virus into the brain

In a recent study, researchers from Uppsala University show that the Semliki Forest virus enters the central nervous system by first entering the cerebrospinal fluid and then binding to a specific cell type before penetrating deeper into the brain.

13 Jan 2025

Inflammasome protects stem cells from becoming cancerous

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, according to a preclinical study by Weill Cornell Medicine investigators.

13 Jan 2025

Gut bacterium associated with reduced dietary sugar intake

This study links Ffar4, gut microbiota, and sugar preference, highlighting potential strategies for managing diabetes and obesity through dietary interventions.

13 Jan 2025

Menarini Group signs licensing deal with Insilico for promising cancer treatment

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

10 Jan 2025

Research explores molecular dynamics of CAR T cells in cancer treatment

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer.

10 Jan 2025

New therapeutic target could boost CAR T-cell therapy success in solid tumors

Russell W. Jenkins, MD, PhD, a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School, is senior author of a new study in Cancer Immunology Research, "TBK1 is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids".

10 Jan 2025